Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model

Clinical Therapeutics
Philippe De WalsDavid Pearce

Abstract

A heptavalent pneumococcal conjugate vaccine (PCV-7) is available to immunize infants against pneumococcal disease. However, a recently developed vaccine, pneumococcal nontypable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV), has recently been licensed. PHiD-CV contains 3 additional Streptococcus pneumoniae serotypes and may provide protection against nontypable H influenzae (NTHi) infection. New health economic models are required to model the impact of PHiD-CV and compare its effectiveness with PCV-7. The aim of this article was to design a model capable of projecting the pneumococcal and NTHi disease burden on the entire UK population under different schedules of PCV-7 and PHiD-CV. This model should also be capable of modeling the net indirect effect of vaccination (ie, the sum of serotype replacement and herd protection). A static, deterministic, age-compartmental model was created based on published information and the input of a board of experts in pneumococcal disease. The model presents results from both a payer-based and societal perspective. A 1-way sensitivity analysis was used to demonstrate the robustness of the model. Key parameters included the case fatality ratio for bacteremia, the hospitalizatio...Continue Reading

References

Dec 13, 1990·The New England Journal of Medicine·S L PomeroyR D Feigin
Sep 25, 1997·JAMA : the Journal of the American Medical Association·P B McIntyreC M Perez
Feb 15, 2001·The New England Journal of Medicine·J EskolaUNKNOWN Finnish Otitis Media Study Group
Apr 12, 2003·Brain : a Journal of Neurology·Stefan Kastenbauer, Hans-Walter Pfister
May 2, 2003·The New England Journal of Medicine·Cynthia G WhitneyUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Jul 5, 2003·Journal of Clinical Microbiology·Joshua M O'NeillGordon E Schutze
Feb 1, 2005·The Lancet Infectious Diseases·William P HausdorffKeith P Klugman
Sep 23, 2006·Expert Review of Vaccines·Stephen P LockhartBernard Fritzell
Jun 29, 2007·The Pediatric Infectious Disease Journal·Rita CardinesMarina Cerquetti
Oct 11, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D TarragóI Obando
Apr 16, 2009·Vaccine·Philippe De WalsMichael E Pichichero
Jun 24, 2009·Vaccine·Ron Dagan

❮ Previous
Next ❯

Citations

Nov 10, 2012·BMC Health Services Research·Mustafa BakırOleksandr Topachevskyi
Jan 22, 2011·PharmacoEconomics·Chantal W B BoonackerMaroeska M Rovers
Nov 23, 2010·Expert Review of Vaccines·Ger T RijkersHeleen van Velzen-Blad
Mar 26, 2011·Expert Review of Vaccines·Tirdad T ZangenehJaffar A Al-Tawfiq
Nov 23, 2012·Expert Review of Vaccines·Raymond A FarkouhDavid R Strutton
Apr 24, 2012·Vaccine·Patricia R Blank, Thomas D Szucs
Jun 7, 2011·Gaceta sanitaria·Raúl MoranoIsabel Pérez Escolano
Sep 29, 2011·Vaccine·Bjarne RobberstadAud K H Berstad
Nov 5, 2016·Vaccine·Kristin A MaurerDavid W Hutton
Jan 6, 2017·International Journal of Health Policy and Management·Federico AugustovskiPaul Kind
Oct 27, 2011·Journal of Medical Economics·Gerhart KnererDavid Pearce
Nov 9, 2017·Human Vaccines & Immunotherapeutics·Xu-Hao ZhangChul-Min Kim
Apr 14, 2021·Value in Health Regional Issues·Jan OlbrechtBaudouin Standaert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.